Clinical trial · Observational
Virtual Biopsy of Prostate Cancer Using PSMA PET and AI
Prostate Cancer Malignancy Grading Using Prostate Specific Membrane Antigen (PSMA) PET and Machine Learning
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prostate cancer is the most common type of cancer in Norwegian men, but many tumors are slow-growing and do not require treatment. Today, MRI is good at detecting suspicious lesions, yet it cannot reliably distinguish aggressive tumors from low-grade ones. As a result, many men undergo repeated invasive biopsies. New PET tracers targeting PSMA improve tumor localization and may correlate with cancer aggressiveness, offering potential for better assessment. This project aims to develop a method to predict Gleason Score non-invasively by applying machine learning to PET and MRI data. The work involves early static and dynamic PSMA PET imaging, tracer kinetic modelling, deep learning, and validation of PET-based measurements of PSMA internalization using ex-vivo cellular methods. If successful, the project could reduce the number of biopsies, improve diagnostic accuracy, offer full 3D assessment of the prostate, shorten clinical workflows, and help identify patients who would benefit most from PSMA-based radioligand therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer (Diagnosis) | Malignant Prostate Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Full length dynamic PET post biopsy
- description
- Patients who are scheduled for a static PET undergoes a full length 60-minute dynamic PET scan during the uptake time before the routine clinical investigation.
- label
- Short dynamic PET and early static PET post biopsy
- description
- Patients who are scheduled for a static PET undergoes a short 15-minute dynamic PET scan during the first part of the uptake time, followed by a static whole body PET scan, before the routine clinical investigation.
- label
- Short dynamic PET and early static PET before biopsies
- description
- Patients who have suspected but not biopsy confirmed prostate cancer will undergo whole body static PET.
Primary outcomes (1)
- measure
- PET imaging
- timeFrame
- 4 hours
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * For patients who have undergone biopsies prior to PET: * Patients referred to clinical PET examination * For patients who have not had biopsies prior to PET: * Patients referred to urologist for suspected prostate cancer based on clinical symptoms or elevated PSA-levels Exclusion Criteria: * Prostatektomy * Body weight under 100 kg * MRI incompatible implants or other incompatibilities
References
Publications (0)
Data not yet available